Dermoklinika-Medyczne Centrum s.c. M.Kierstan J.Narbutt A.Lesiak

Lodz 18 trials 4 recruiting

18 Registered trials

4 Currently recruiting

Organisation

Dermoklinika-Medyczne Centrum s.c. M.Kierstan J.Narbutt A.Lesiak

Location

Lodz, Poland

Identifier

ORG-100040989

Address

Al. Tadeusza Kosciuszki 93, 90-436, Poland

Departments

2301:Allergology
Dermatology
Dermoklinika-Medyczne Centrum s.c. M.Kierstan J. Narbutt A. Lesiak
Dermoklinika, Centrum Medyczne
Klinika Dermatologii
N/A
NA
not applicable

Clinical trials at this site (18)

Search interface

Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Not authorised

2023-503522-40-00 Atopic Dermatitis 4
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting

2023-504863-17-00 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic 5 2024-02-21
24 weeks double-blind randomized placebo-controlled trial to evaluate efficacy, PK, safety of LOU064 in adolescents (12 - <18) with CSU and … Recruiting

2022-502159-78-00 Chronic Spontaneous Urticaria 5 2023-12-06
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoria… Recruiting

2022-500408-22-00 Plaque Psoriasis 5 2022-09-14
A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects with Moderate to… Recruiting

2022-502519-13-00 Moderate to Severe Plaque Psoriasis 5 2021-05-07
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended

2022-502700-78-00 Alopecia areata (AA) 5 2023-09-01
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended

2023-503522-40-01 Atopic Dermatitis 4 2024-04-10
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-502461-23-00 Prurigo Nodularis 5 2024-02-15
Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended

2023-504346-66-00 Dermatitis atopic 4 2024-02-14
A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade… Ended

2023-504328-25-00 hidradenitis suppurativa 4 2023-12-27
Hidradenitis Suppurativa Phase 3 Study of Izokibep Ended

2022-503160-33-00 Hidradenitis Suppurativa 5 2023-12-15
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss. Ended

2023-504421-39-00 Androgenetic Alopecia 5 2023-11-21
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Ended

2022-502888-38-00 Atopic dermatitis 4 2023-09-25
A study to understand how well DC806 works and how safe it is in participants with plaque psoriasis Ended

2022-502249-90-00 Plaque Psoriasis 4 2023-08-31
A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo Ended

2022-501668-16-00 NON SEGMENTAL VITILIGO 5 2023-06-26
A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera… Ended

2022-502575-30-00 Atopic Dermatitis 5 2023-05-23
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended

2022-501850-12-00 Psoriasis 4 2023-03-15
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea… Ended

2023-504156-10-00 Plaque Psoriasis. 5 2021-08-13